Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huwentoxin-I (HWAP-I) is a 33-amino acid peptide toxin originally isolated from the venom of the Chinese bird spider (*Haplopelma huwenum*, also known as *Cyriopagopus schmidti*). It functions as a potent and selective antagonist of N-type voltage-gated calcium channels (CaV2.2). These channels are primarily located in the presynaptic terminals of primary afferent neurons in the dorsal horn of the spinal cord, where they play a critical role in the transmission of pain signals. By blocking CaV2.2, HWAP-I inhibits the release of pro-nociceptive neurotransmitters such as glutamate and substance P, thereby providing significant analgesic effects. Developed by Xiamen Beida Zhi Road Bioengineering, HWAP-I has been investigated in clinical trials for the management of severe chronic pain, particularly cancer-related pain, as a non-opioid alternative with a mechanism of action similar to ziconotide.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on huwentoxin-I.